相关实验视频
Updated: Jul 26, 2025

06:25
Stereoacuity Improvement using Random-Dot Video Games
Published on: January 14, 2020
14.4K
通过多尼佩西尔治疗视的长期康复.
Carolyn Wu1,2, Eric D Gaier3,4,5, Bharti R Nihalani3,4
1Department of Ophthalmology, Boston Children's Hospital, Boston, MA, USA. carolyn.wu@childrens.harvard.edu.
Scientific reports
|June 22, 2023
概括
唐纳,一种乙胆酶抑制剂 (AChEI),改善了老年儿童和残留视的成年人的视力. 这种治疗增强了神经可塑性,表明药理学操纵可以克服视觉恢复的关键窗口.
科学领域:
- 眼科医生 眼科 眼科
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 较高的神经可塑性值限制了老年羊眼患者的视力恢复.
- 乙胆酶抑制剂 (AChEI) 在动物模型中显示出增强视觉神经可塑性和治疗盲视的潜力.
研究的目的:
- 为了调查多尼,一个常见的ACHEI,可以恢复视觉功能在老年儿童和残留视的成年人.
- 评估donepezil在治疗常见的临界期之外的眼盲的安全性和有效性.
主要方法:
- 一项开放的试点研究治疗了16名残留野视的参与者 (9-37岁),他们每天使用口服多尼佩西尔治疗了12周.
- 剂量根据年龄和视力敏度响应进行调整,对18岁以下的参与者进行补丁.
- 视觉敏度在治疗结束后的22周,10周后被测量.
主要成果:
- 眼眼中的平均视敏度提高了1.2线.
- 25%的参与者 (4/16) 取得了≥2线改善.
- 在停止服用多尼西尔10周后,视觉效果保持不变,并且在不同年龄组一致.
结论:
- 多尼西尔治疗导致较年长的儿童和残留视的成年人显著改善视力.
- 这些发现支持药理干预的潜力,以增强视觉皮层可塑性和治疗眼盲.
- 需要进一步的安慰剂对照试验来证实这些初步结果.
相关概念视频
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Open Angle Glaucoma: Treatment
481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Angle Closure Glaucoma: Treatment
577
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
577
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
163
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
163

